Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11 12 13

4 décembre 2017

10:00
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the first patient has been enrolled into a Phase 1 cancer study of Morphotek's antibody-drug conjugate (ADC) MORAb-202.  The Phase 1 trial, which is being conducted in Japan and...

09:49
Mallinckrodt plc , a leading global specialty pharmaceutical company, announced results from a retrospective, claims-based analysis providing health economic insights on the use of medication and healthcare resource utilization (HCRU) among patients...

09:15
BioPharmX Corporation , a specialty pharmaceutical company developing products for the dermatology market, will share research suggesting that BPX-01, the company's topical gel formulation of minocycline, may exhibit relevant antimicrobial and...

09:00
Expanding Orthopedics Inc. (EOI), a privately held medical device company focused on developing and commercializing innovative expandable devices for spine surgery, is proud to announce that Dr. Adam Lewis of Jackson MS is the first surgeon in...

09:00
Spruce Biosciences, a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for SPR001 for the treatment of...

09:00
ChemomAb, the bio-pharmaceutical start-up, has completed a $10 million fund raising round led by OrbiMed Israel and Peter Thiel. SBI Japan-Israel Innovation Fund and Milestone Venture also participated in the round. This was the second round of...

09:00
Pairnomix, LLC and KCNQ2 Cure Alliance today announced that findings from a new case study for a patient with KCNQ2 epilepsy were presented at the 71st Annual Meeting of the American Epilepsy Society in Washington, DC, December 1-5, 2017. Using...

08:45
ClearLight Diagnostics, LLC, a developer of an automated next generation tissue processing and 3D imaging platform, announced today that it will present data at the 2017 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. Poster...

08:30
Propanc Biopharma Inc. ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and...

08:30
Ava, a medical technology company best known for its popular cycle-tracking Ava bracelet, announced, in collaboration with the University Hospital of Zurich, the initiation of a clinical trial monitoring women with highly irregular cycles ? including...

08:30
Therapix Biosciences Ltd. , a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based therapies, announces the completion of enrollment in its investigator-initiated Phase IIa study at Yale University...

08:03
AbbVie , a global research and development-based biopharmaceutical company, today announced positive top-line results from IMMhance, the fourth pivotal Phase 3 clinical trial evaluating risankizumab (150 mg) for the treatment of patients with...

08:02
Kindred Biosciences, Inc. , a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pivotal field effectiveness study of Zimetatm (dipyrone oral gel) for the control of pyrexia...

08:00
Eone-Diagnomics Genome Center (EDGC), a Korean genetic analysis company, said today that it has started applying machine learning-based Artificial Intelligence (AI) technology to its non-invasive prenatal testing (NIPT) NICE®. This is the first time...

08:00
BioSight, Ltd, a pharmaceutical development company, focused on the development of targeted oncology therapeutics with reduced toxicity, is pleased to announce the results of a Phase I/II clinical study of BST-236 in acute leukemia patients have been...

07:30
Further improvement in disease symptoms and fracture healing observed through 48 weeks of treatment with burosumab   Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company focused on the development of novel products for rare and...

07:03
Moffitt Cancer Center announced that last week it treated the first patient commercially in the United States with the recently Food and Drug Administration-approved Yescartatm, a Chimeric Antigen Receptor T cell, or CAR-T, therapy for patients with...

07:01
Sanofi's Toujeo® met the primary study objective in the first large head-to-head clinical trial1, called BRIGHT study, comparing Toujeo with insulin degludec. Sanofi plans to provide full results in 2018. The primary objective was to determine if...

07:00
BioLineRx Ltd. , a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today positive overall survival data from the long-term follow-up part of the Phase 2a trial of BL-8040 for the treatment of relapsed or...

07:00
Today, Weight Watchers International, Inc.  launches WW Freestyle, a new program that builds on the highly successful and effective SmartPoints® system by expanding zero Points foods from only fruits and vegetables to a list of more than 200...

06:48
Bayer and Loxo Oncology, Inc., , today announced updated clinical data from the larotrectinib (LOXO-101) pediatric Phase I SCOUT trial (NCT02637687). These data are being presented today at the American Association for Cancer Research (AACR) Special...

03:06
First oral short-course treatment for relapsing- remitting multiple sclerosis (RRMS) now approved in Canada, which has one of the highest rates of MS in the world[1]  Mavencladhas shown sustained clinical efficacy with a duration of oral treatment...

02:00
Atox Bio, a clinical stage biotechnology company developing novel therapies for critically ill patients, today announced that it has raised $30 million. The round was led by Arix Bioscience plc with participation from Adams Street Partners, Asahi...

01:53
New findings from an indirect comparison between Xultophy® and IGlarLixi published in the Journal of Medical Economics show that treatment with Xultophy® (insulin degludec/liraglutide) provides statistically significant greater reductions in blood...


2 décembre 2017

12:00
Evogen, Inc., a leader in proteomics and genomics-based testing for improved diagnosis and treatment of neurological disorders, today reported that a clinical study to be presented at the 2017 Annual Meeting of the American Epilepsy Society (AES)...

04:00
FOR MEDICAL AND TRADE MEDIA ONLY   Absolute PASI analysis from the VOYAGE 1 trial shows a high level of skin responses were maintained through two years in patients treated with guselkumab    Additional new data show a consistent safety profile...


1 décembre 2017

22:30
Xynomic Pharma, a clinical stage US oncology drug development company, today announced that it will initiate a Ph 1/2 trial, in collaboration with Janssen R&D, LLC (Janssen Pharmaceutical Companies of Johnson & Johnson, hereafter Janssen) and...

15:19
Fumoir Grizzly, en compagnie de ses partenaires l'Université Laval et Merinov, annonce qu'il a maintenant complété le développement de la bactériocine M35 et la mise au point de son procédé d'application. Appelé Bac M35, ce bio-ingrédient entièrement...

15:16
Fumoir Grizzly, with partners Université Laval and Merinov, announced that it has completed development of the M35 bacteriocin and its application process. Named Bac M35, this completely natural bioingredient protects fish from growing Listeria...

12:34
The facts about prostate cancer can be confusing. It's the third most common cancer type among Americans?161,000 men will be diagnosed this year, the National Cancer Institute estimates. Yet according to the NCI, 98.6% will be alive in 5 years....

10:01
Company supports FDA recommendation for lab, clinician and patient education about reporting all prescription medication and supplements prior to blood draws. Education on potential interferences in lab testing is important in mitigating risk...

09:00
Given the growing use and cost of multiple sclerosis (MS) medicines, Prime Therapeutics LLC (Prime), a leading pharmacy benefit manager (PBM), and Biogen, a market leader of medicines to treat MS, have partnered on an outcomes-based contract for...

09:00
sphingotec GmbH , a biotechnology company that develops biomarkers for the detection and management of diseases, has recently signed an agreement with Mayo Clinic to collaborate on the evaluation and use of several biomarkers that may improve the...

08:30
U.S. Stem Cell, Inc. , a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer Dr. Kristin Comella will present at the Healthy Masters...

08:08
Influenzavirus B Infections Global Clinical Trials Review, H2, 2017SummaryGlobalData's clinical trial report, "Influenzavirus B Infections Global Clinical Trials Review, H2, 2017" provides an overview of Influenzavirus B Infections clinical trials...

07:05
RXi Pharmaceuticals Corporation a clinical-stage company developing a new class of RNAi-based therapeutics and the Center for Cancer Immune Therapy (CCIT) at Herlev Hospital, a leading European center for use of tumor infiltrating lymphocytes (TIL)...

05:00
Researchers using CT scans and 3-D printing have created accurate, custom-designed prosthetic replacements for damaged parts of the middle ear, according to a study being presented today at the annual meeting of the Radiological Society of North...

02:29
InDex Pharmaceuticals Holding AB (publ) today announced new scientific data on the mechanism of action of cobitolimod, the company's lead drug candidate. The findings show that cobitolimod can modulate the immune system in ulcerative colitis by...


30 novembre 2017

23:57
Nippon Chemiphar Co., Ltd. a annoncé que l'essai clinique de phase 1 du NC-2500, un inhibiteur de la xanthine oxydoréductase (XOR) novateur, a été terminé, indiquant qu'il a le potentiel pour réduire le risque de crise de goutte, l'un des problèmes...

22:30
Inguinal Hernia Global Clinical Trials Review, H2, 2017SummaryGlobalData's clinical trial report, "Inguinal Hernia Global Clinical Trials Review, H2, 2017" provides an overview of Inguinal Hernia clinical trials scenario. This report provides top...

22:29
Ileus (Intestinal Obstruction) Global Clinical Trials Review, H2, 2017Summary Read the full report: https://www.reportlinker.com/p04584178 GlobalData's clinical trial report, "Ileus (Intestinal Obstruction) Global Clinical Trials Review, H2, 2017"...

22:29
Incisional (Ventral) Hernia Global Clinical Trials Review, H2, 2017SummaryGlobalData's clinical trial report, "Incisional (Ventral) Hernia Global Clinical Trials Review, H2, 2017" provides an overview of Incisional (Ventral) Hernia clinical trials...

22:28
Idiopathic Short Stature Global Clinical Trials Review, H2, 2017Summary GlobalData's clinical trial report, "Idiopathic Short Stature Global Clinical Trials Review, H2, 2017" provides an overview of Idiopathic Short Stature clinical trials scenario....

22:27
Frontier Pharma: Neurodegenerative Diseases - Protein Misfolding Targets and Neuromodulators Dominate the First-in-Class Pipeline and Lead the Way as Potential Disease-Modifying Therapies in AD and PDRead the full report:...

22:27
Infectious Diarrhea Global Clinical Trials Review, H2, 2017SummaryGlobalData's clinical trial report, "Infectious Diarrhea Global Clinical Trials Review, H2, 2017" provides an overview of Infectious Diarrhea clinical trials scenario. This report...

21:58
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Global Clinical Trials Review, H2, 2017Read the full report: https://www.reportlinker.com/p03340774SummaryGlobalData's clinical trial report, "Idiopathic Thrombocytopenic Purpura...

21:53
Induced Abortion Global Clinical Trials Review, H2, 2017 SummaryGlobalData's clinical trial report, "Induced Abortion Global Clinical Trials Review, H2, 2017" provides an overview of Induced Abortion clinical trials scenario. This report provides...

21:46
Impetigo Global Clinical Trials Review, H2, 2017 SummaryGlobalData's clinical trial report, "Impetigo Global Clinical Trials Review, H2, 2017" provides an overview of Impetigo clinical trials scenario. This report provides top line data relating to...

18:20
Bayer today announced that an Independent Data Monitoring Committee (IDMC) has recommended to unblind a Phase III trial of radium Ra 223 dichloride (radium-223) in combination with abiraterone acetate and prednisone/prednisolone in prostate cancer....

17:23
TesoRx Pharma LLC, a biopharmaceutical company, today announced it commenced enrollment for a Phase 1/2a clinical trial of TSX-011 in patients with hypogonadism. TSX-011 is a novel oral testosterone replacement therapy ("TRT") to treat adult males...

1 2 3 4 5 6 7 8 9 10 11 12 13